Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose-Reference-Cited by-同舟云学术

Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose

Published:2019-03-14 Issue:1 Volume:65 Page:132-137
ISSN:1355-008X
Container-title:Endocrine
language:en
Short-container-title:Endocrine

Author:

Campennì Alfredo^ORCID,Amato Ernesto,Laudicella Riccardo^ORCID,Alibrandi Angela,Cardile Davide,Pignata Salvatore Antonio,Trimarchi Francesco,Ruggeri Rosaria Maddalena,Auditore Lucrezia,Baldari Sergio

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1007/s12020-019-01897-x.pdf

Reference25 articles.

1. F. Pacini, F. Basolo, R. Bellantone, G. Boni, M.A. Cannizzaro, M. De Palma, C. Durante, R. Elisei, G. Fadda, A. Frasoldati, L. Fugazzola, R. Guglielmi, C.P. Lombardi, P. Miccoli, E. Papini, G. Pellegriti, L. Pezzullo, A. Pontecorvi, M. Salvatori, E. Seregni, P. Vitti, Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies. J. Endocrinol. Invest. 41(7), 849–876 (2018)

2. A. Campennì, L. Giovanella, A. Alibrandi, M. Siracusa, R.M. Ruggeri, S. Baldari, BRAF (V600E) mutation in isthmic malignant thyroid nodules. Clin. Endocrinol. 84(1), 152–153 (2016)

3. A. Campennì, L. Giovanella, M. Siracusa, M.E. Stipo, A. Alibrandi, M. Cucinotta, R.M. Ruggeri, S. Baldari, Is malignant nodule topography an additional risk factor for metastatic disease in low-risk differentiated thyroid cancer? Thyroid 24(11), 1607–1611 (2014)

4. R. Gallicchio, S. Giacomobono, D. Capacchione, A. Nardelli, F. Barbato, A. Nappi, T. Pellegrino, G. Storto, Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation? Endocrine 44(2), 426–433 (2013)

5. R.M. Tuttle, H. Tala, J. Shah, R. Leboeuf, R. Ghossein, M. Gonen, M. Brokhin, G. Omry, J.A. Fagin, A. Shaha, Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20(12), 1341–1349 (2010)

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Theranostics of Thyroid Cancer;Seminars in Nuclear Medicine;2024-07

2. False-positive radioiodine uptake after radioiodine treatment in differentiated thyroid cancer;Endocrine;2023-03-16

3. Recombinant or endogenous thyroid-stimulating hormone for radioactive iodine therapy in thyroid cancer: state of knowledge and current controversies;European Journal of Endocrinology;2023-01-19

4. Thyroid and Parathyroid Cancer;Multimodality Imaging and Intervention in Oncology;2023

5. Strategies for Radioiodine Treatment: What’s New;Cancers;2022-08-04